Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Rupatadine fumarate
Cat. No.:
OB0225LY-0096
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
Rupatadine fumarateis an antihistamine primarily used in the treatment of allergic diseases, as its salt form fumarate enhances its stability.
Synonym:
Rinialer; Rupafin; Alergoliber; 182349-12-8; 5H-Benzo[5,6]cyclohepta[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene]-, (2E)-2-butenedioate (1:1); 8-Chloro-11-(1-((5-methylpyridin-3-yl)methyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine fumarate
CAS No.:
182349-12-8
Compound CID:
6449107
Formula:
C26H26ClN3·C4H4O4
Formula Weight:
532.03
Specification
Relative Density:
1.248 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Rupatadine fumarate can be used as a potent dual PAF/H1 antagonist.
Library Information
Targets:
PAFR; Histamine receptor
Receptors:
H1 receptor
Pathways:
GPCR/G protein; Autophagy; Immunology/Inflammation; Neuronal signaling
Plate Number:
AOCL-2
Plate Location:
b9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
12 mg/mL; 22.56 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
11 mg/mL; 20.7 mM
